Procalcitonin expands chemistry menu

Beckman Coulter Diagnostics has entered a partnership with Diazyme Laboratories that allows customers access to a procalcitonin (PCT) assay, an important marker for the detection and management of bacterial infections and sepsis. The high-quality, fully automated PCT assay is available for use with Beckman Coulter AU analysers (models 480, 680 and 5800).

Sepsis begins outside the hospital setting in nearly 80% of patients. A Centers for Disease Control and Prevention evaluation found seven in 10 patients with sepsis had recently used healthcare services or had chronic diseases requiring frequent medical care. “Fast diagnosis and treatment is critical for patients with sepsis,” said Dr Mike Samoszuk (Beckman Coulter Diagnostics). “Adding PCT to our chemistry menu offers a tool for detecting and managing bacterial infections and sepsis, which should inform the course and prognosis of the disease and facilitate therapeutic decisions. This addition is a result of our commitment to providing disease state management solutions.”

This assay is the first homogenous PCT assay for use on current Beckman Coulter AU model chemistry analysers, eliminating the need for costly dedicated instrumentation. The assay features a latex-enhanced immunoturbidimetric methodology, which uses multiple monoclonal antibodies for enhanced assay sensitivity and specificity.

www.beckman.com

 

Other news

Upcoming Events

Biosafety Practitioner Level 1 Training Course

Public Health England
15-19 January 2018

British Society for Microbial Technology Annual Scientific Conference

Public Health England, Colindale, London
18 May 2018

Pathology Horizons 2018 Conference

Lough Erne Resort, Co. Fermanagh, Northern Ireland
September 13-15

Microbe 2018

Hilton Hotel, Sheffield
21-23 September 2018

Latest Issue

Pathology In Practice

Pathology In Practice

Aug 2017

Screening for haemoglobinopathies

Register now to apply for regular copies of Pathology In Practice and free access to premium content, as well as our regular newsletters.